OKUR OnKure Therapeutics (OKUR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001637715
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
55
13F, latest reported quarter
What the filings say about OKUR
Insiders, 180 days
-$2.9K net sold
2 sellers · 0% of sales under a 10b5-1 plan
OnKure Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, OnKure Therapeutics, Inc. insiders sold a net $2.9K of stock across 20 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 22, 2026.
- The trade is 1.6% of the 18,500 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Leverone Jason A. sold about $898 of OKUR on Sep 21, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 22, 2026.
- The trade is 0.8% of the 11,160 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Saccomano Nicholas A sold about $259 of OKUR on Sep 21, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 23, 2026.
- The trade is 0.8% of the 11,247 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Saccomano Nicholas A sold about $378 of OKUR on Jun 22, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 23, 2026.
- The trade is 1.6% of the 18,802 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Leverone Jason A. sold about $1.3K of OKUR on Jun 22, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Dec 22, 2025.
- The trade is 1.2% of the 7,333 shares held after it.
- 1 other insider sold within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Saccomano Nicholas A sold about $358 of OKUR on Mar 23, 2026; 1 other insider sold within 30 days and 55 funds added in the latest 13F quarter.20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.9K over 180 days
-$1.2K over 90 days
more than 63% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
55 funds bought in last quarter
below 51% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.5% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
below 60% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch OKUR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-15.4%12M
Insider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns OKUR: institutional holders (13F)
13F holdings, latest reported quarter
3,998,333 sh
$18.2M
3,235,778 sh
$14.8M
2,839,674 sh
$12.9M
2,660,612 sh
$12.1M
2,238,684 sh
$10.2M
Congress trades in OKUR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
AI Biotechnology LLC
Activist 13D · 2026-04-07
19.99%
Access Industries Holdings LLC
Activist 13D · 2026-04-07
19.99%
Access Industries Management, LLC
Activist 13D · 2026-04-07
19.99%
Len Blavatnik
Activist 13D · 2026-04-07
19.99%
OKUR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
OKUR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
T. Rowe Price Health Care ETF
$69.9K position · as of 2026-06-30
0.3%
Ultra-Small Company Market Fund
$155.0K position · as of 2026-06-30
0.1%
Ultra-Small Company Fund
$74.3K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$360.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$24.0K position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$166.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.9K sold by insiders over 180 days, 55 funds added last quarter. Each figure is a federal filing, dated the day it went public.
OKUR financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM OKUR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM OKUR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$47.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM OKUR
| FY Dec 2025 | -$51.9M |
| FY Dec 2024 | -$51.2M |
| FY Dec 2023 | -$34.8M |
| FY Dec 2022 | -$47.7M |
| FY Dec 2021 | -$38.2M |
| Jun 2026 | -$10.4M |
| Mar 2026 | -$12.9M |
| Dec 2025 | -$11.5M |
| Sep 2025 | -$13.0M |
| Jun 2025 | -$13.3M |
| Mar 2025 | -$14.0M |
| Dec 2024 | -$23.4M |
| Sep 2024 | -$10.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity OKUR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt OKUR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-46.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity OKUR
| FY Dec 2025 | -74.4% |
| FY Dec 2024 | -5,304% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -112.0% |
| FY Dec 2021 | -75.7% |
| Jun 2026 | -46.9% |
| Mar 2026 | -42.7% |
| Dec 2025 | -74.4% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -5,304% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-44.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets OKUR
| FY Dec 2025 | -67.2% |
| FY Dec 2024 | -69.9% |
| FY Dec 2023 | -49.1% |
| FY Dec 2022 | -39.6% |
| FY Dec 2021 | -38.0% |
| Jun 2026 | -44.2% |
| Mar 2026 | -39.4% |
| Dec 2025 | -67.2% |
| Sep 2025 | -84.3% |
| Jun 2025 | -73.2% |
| Mar 2025 | -64.0% |
| Dec 2024 | -69.9% |
| Sep 2024 | -16.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital OKUR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-49.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed OKUR
| FY Dec 2025 | -78.4% |
| FY Dec 2024 | -81.9% |
| FY Dec 2023 | -57.0% |
| FY Dec 2022 | -43.3% |
| FY Dec 2021 | -40.1% |
| Jun 2026 | -49.5% |
| Mar 2026 | -44.7% |
| Dec 2025 | -78.4% |
| Sep 2025 | -95.8% |
| Jun 2025 | -81.5% |
| Mar 2025 | -71.2% |
| Dec 2024 | -81.9% |
| Sep 2024 | -15.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing OKUR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.04x |
| Mar 2025 | 0.31x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value OKUR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-46.9%
TTM free cash flow over market value at close 2026-10-23
FCF yield OKUR
| FY Dec 2025 | -53.5% |
| FY Dec 2024 | -17.8% |
| FY Dec 2023 | -6.5% |
| FY Dec 2022 | -8.3% |
| FY Dec 2021 | -1.8% |
| Jun 2026 | -26.0% |
| Mar 2026 | -89.7% |
| Dec 2025 | -53.5% |
| Sep 2025 | -69.3% |
| Jun 2025 | -76.8% |
| Mar 2025 | -38.0% |
| Dec 2024 | -17.8% |
| Sep 2024 | -3.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing OKUR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $0 | n/a | n/a |
| Operating income | -$63.0M | -$54.4M | -$36.9M | -$53.8M |
| Net income | -$59.5M | -$52.7M | -$35.3M | -$52.0M |
| EPS (diluted) | -4.40 | -15.28 | -124.41 | -2.12 |
| Operating cash flow | -$51.8M | -$51.1M | -$34.5M | -$47.4M |
| Cash | $59.0M | $110.8M | $29.9M | $19.9M |
| Buybacks | n/a | n/a | $4.4M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
OKUR Stock Sonar score 4/7 axes
Find similar shapesCompareOKUR ranks highest on risk and compliance (63rd percentile) and profitability (52nd), and lowest on insider conviction (31st), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OKUR filings, in plain words
Are OnKure Therapeutics insiders buying or selling OKUR?
In the 180 days to 2026-10-28, OnKure Therapeutics insiders were net sellers, a net $2.9K across purchases and sales reported on Form 4, by 2 sellers.
Read the full summary
In the 180 days to 2026-10-28, OnKure Therapeutics insiders were net sellers of OKUR, a net $2.9K across purchases and sales reported on Form 4 by 2 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. The latest 5% ownership filing is a 13D by AI Biotechnology LLC, filed 2026-04-07, for 20.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
